Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors.
A study was performed on 184 patients with superficial bladder cancer (pTa, pT1), 92 with primary and 92 recurrent tumors. After TUR of all visible lesions, endovesical chemotherapy with thiotepa, adriamycin or cis-platinum was started on the 15th and 30th days following surgery. There were no statistically significant differences between any of the three chemotherapies at the doses and intervals mentioned. Only cis-platinum has proven to be more effective in primary high grade tumor.
D002945:Cisplatin / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D004341:Drug Evaluation; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011182:Postoperative Care; D013852:Thiotepa / Q000008:administration & dosage*; D013997:Time Factors; D001743:Urinary Bladder; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control* / Q000601:surgery
D004317:Doxorubicin; D013852:Thiotepa; D002945:Cisplatin